Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis

Stefan Janik; Christine Bekos; Philipp Hacker; Thomas Raunegger; Bahil Ghanim; Elisa Einwallner; Lucian Beer; Walter Klepetko; Leonhard Müllauer; Hendrik J. Ankersmit; Bernhard Moser

doi:10.18632/oncotarget.17478

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis

Stefan Janik, Christine Bekos, Philipp Hacker, Thomas Raunegger, Bahil Ghanim, Elisa Einwallner, Lucian Beer, Walter Klepetko, Leonhard Müllauer, Hendrik J. Ankersmit and Bernhard Moser _

PDF | HTML | How to cite

Oncotarget. 2017; 8:47090-47102. https://doi.org/10.18632/oncotarget.17478

Metrics: PDF 1748 views | HTML 3654 views | ?

Abstract

Stefan Janik1,2, Christine Bekos1,2, Philipp Hacker1,2, Thomas Raunegger1,2, Bahil Ghanim1, Elisa Einwallner3, Lucian Beer2,4, Walter Klepetko1, Leonhard Müllauer5, Hendrik J. Ankersmit1,2 and Bernhard Moser1

1Department of Thoracic Surgery, Division of Surgery, Medical University of Vienna, Vienna, Austria

2Christian Doppler Laboratory for Diagnosis and Regeneration of Cardiac and Thoracic Diseases, Medical University of Vienna, Vienna, Austria

3Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria

4Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria

5Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria

Correspondence to:

Bernhard Moser, email: [email protected]

Keywords: thymic epithelial tumors, thymoma, thymic carcinoma, CRP, prognosis

Received: November 11, 2016 Accepted: April 12, 2017 Published: April 27, 2017

ABSTRACT

Objective: Scarce information exists on the pathogenesis of thymic epithelial tumors (TETs), comprising thymomas, thymic carcinomas (TCs) and neuroendocrine tumors. C-reactive protein (CRP) increases during certain malignancies. We aimed to investigate the clinical relevance of CRP in patients with TETs.

Results: Pretreatment CRP serum concentrations were significantly elevated in patients with TETs, particularly TCs and metastatic TETs. After complete tumor resection CRP serum concentrations were decreased (p = 0.135) but increased significantly in case of tumor recurrence (p = 0.001). High pretreatment CRP was associated with significantly worse 5- and 10-year freedom-from recurrence (FFR) (p = 0.010) and was a negative prognostic factor for FFR (HR 3.30; p = 0.015). IL-6 (not IL-1β) serum concentrations were significantly elevated in patients with TETs but we did not detect CRP tissue expression in TETs.

Materials and Methods: Pretreatment CRP serum concentrations were retrospectively analyzed from 128 surgical patients (1990–2015). In a subset of 68 patients longitudinal analysis of CRP was performed. Additionally, immunohistochemical tumor CRP expression and serum concentrations of interleukin (IL)-6 and IL-1β were measured.

Conclusions: Hence, diagnostic measurement of serum CRP might be useful to indicate highly aggressive TETs and to make doctors consider tumor recurrences during oncological follow-up.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17478

Publication Alerts

Research Papers:

Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis

Abstract